TY - JOUR
T1 - MicroRNAs and other non-coding RNAs as targets for anticancer drug development
AU - Ling, Hui
AU - Fabbri, Muller
AU - Calin, George A.
N1 - Funding Information:
G.A.C. is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. He is also supported as a Fellow at The University of Texas MD Anderson Research Trust, as a University of Texas System Regents Research Scholar and by the CLL Global Research Foundation. Work in G.A.C.’s laboratory is supported in part by the US National Institutes of Health (NIH)/US National Cancer Institute (NCI) grant CA135444; a US Department of Defense Breast Cancer Idea Award; Developmental Research Awards in breast cancer, ovarian cancer, brain cancer, prostate cancer, multiple myeloma and leukaemia (P50 CA100632) as well as head and neck cancer (P50 CA097007) from the Specialized Programs of Research Excellence (SPOREs); a Sister Institution Network Fund (SINF) grant from the MD Anderson Cancer Center and the German Cancer Research Center (DKFZ) in chronic lymphocytic leukaemia; a SINF grant in colorectal cancer, the Laura and John Arnold Foundation; the RGK Foundation; and The Estate of C. G. Johnson, Jr. H.L. is an Odyssey Fellow and his work is supported in part by the Odyssey Program and The Estate of C. G. Johnson, Jr. M.F.’s laboratory is supported by the Jean Perkins Foundation, by Nautica Malibu Triathlon Funds, by the Pablove Foundation, by the St. Baldrick’s Foundation, by the Southern California Clinical and Translational Science Institute, by Funds from the Saban Research Institute, by award number P30CA014089 from the NCI, by the Hugh and Audy Lou Colvin Foundation, and by the T. J. Martell Foundation. The authors apologize to all colleagues whose work was not cited because of space restrictions.
PY - 2013/11
Y1 - 2013/11
N2 - The first cancer-targeted microRNA (miRNA) drug-MRX34, a liposome-based miR-34 mimic-entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
AB - The first cancer-targeted microRNA (miRNA) drug-MRX34, a liposome-based miR-34 mimic-entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April 2013, and miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although miRNAs are the most studied non-coding RNAs (ncRNAs) to date, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here, we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.
UR - http://www.scopus.com/inward/record.url?scp=84887101163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887101163&partnerID=8YFLogxK
U2 - 10.1038/nrd4140
DO - 10.1038/nrd4140
M3 - Review article
C2 - 24172333
AN - SCOPUS:84887101163
SN - 1474-1776
VL - 12
SP - 847
EP - 865
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 11
ER -